Neuralink, the brain implant company co-founded by Elon Musk, has received approval from the US Food and Drug Administration (FDA) to begin testing its new device, called Blindsight. This brain chip aims to offer a solution to people who have lost their vision due to optic nerve damage.
Classified by the FDA as an “advanced device,” Blindsight marks a major step forward in neurotechnology research. The company is already receiving requests from volunteer patients who are interested in participating in the tests, which can be done directly on the Neuralink website. However, the company has not yet announced dates to start tests or perform surgeries.
Although expectations are high, Musk clarified that in the early stages, the chip will give a “low resolution” look, compared to the graphics of old Atari games. The long-term goal, according to the founder of Neuralink, is to develop a device that could eventually surpass human vision, allowing vision of spectra such as infrared and ultraviolet.
Neuralink already has experience with brain implants, having successfully performed the second procedure on people, which allowed a volunteer to interact with 3D modeling software and play simple games. However, the first implant, despite being successful at first, later developed defects.
2024-09-21 15:09:00
#FDA #approves #Neuralink #brain #chip #restore #vision #blind #patients
